Nuvation Bio Inc. (NUVB) Stock Price & How to Invest
Last updated July 2026
Short answer
NUVB is Nuvation Bio, a commercial-stage oncology company whose lead drug IBTROZI (taletrectinib) won full FDA approval in 2025 for ROS1-positive lung cancer, so the story is now about turning an approved product plus global partner deals into durable revenue rather than betting on trial data.
NUVB stock price
As of 2026-07-20, Nuvation Bio Inc. (NUVB) last closed at $6.26, up 166.4% over the past year. Over the past 52 weeks it has traded between $2.23 and $9.54.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Nuvation Bio Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Nuvation Bio Inc. (NUVB) do?
Nuvation Bio (NYSE: NUVB) is a San Francisco oncology company founded by David Hung, best known for previously building and selling Medivation. Its commercial anchor is IBTROZI (taletrectinib), a next-generation oral ROS1 tyrosine kinase inhibitor that received full FDA approval in June 2025 for locally advanced or metastatic ROS1-positive non-small cell lung cancer across lines of therapy. The drug is positioned against first-generation options like Pfizer's Xalkori and Roche's Rozlytrek and the newer Bristol Myers Squibb agent Augtyro, and it has been added as a preferred option in NCCN guidelines. Beyond IBTROZI, the pipeline includes safusidenib (a brain-penetrant IDH1 inhibitor), NUV-1511 (a drug-drug conjugate), and NUV-868 (a BET inhibitor).
The investment picture is a transition from cash-burning developer to revenue-generating commercial company. IBTROZI net U.S. product revenue was about $18.5 million in Q1 2026, up roughly 18% sequentially, with more than 600 patients started on the drug since launch. Nuvation has layered on ex-U.S. licensing deals (Eisai for Europe and other markets, Innovent in China where it sells as Dovbleron, and Nippon Kayaku in Japan) that bring upfront payments, milestones, and royalties. A large one-time Eisai upfront pushed reported Q1 2026 revenue to about $83 million and produced a rare quarterly profit, but the underlying recurring product sales are still modest and building.
What's driving Nuvation Bio Inc. (NUVB)?
1. IBTROZI commercial ramp
The core driver is uptake of IBTROZI in ROS1-positive NSCLC, a targeted but real U.S. patient population. Sequential product revenue growth and a rising share of first-line patients suggest the launch is gaining traction, and NCCN preferred-option status supports prescribing.
2. Global partner economics
Licensing deals with Eisai, Innovent, and Nippon Kayaku extend taletrectinib into Europe, China, and Japan without Nuvation funding those launches directly. These arrangements carry combined upfronts and milestones exceeding roughly $300 million plus tiered mid-teen to low-twenties royalties, providing non-dilutive revenue as approvals expand.
3. Label and geographic expansion
The FDA accepted a supplemental NDA for IBTROZI with a target action date in early 2027, and the EMA validated the European marketing application. Broader approvals could enlarge the addressable population over time.
4. Pipeline optionality
Assets like safusidenib, NUV-1511, and NUV-868 give the company additional oncology shots on goal beyond taletrectinib, though these remain earlier-stage and unproven.
What are the risks to Nuvation Bio Inc. (NUVB)?
IBTROZI targets a relatively small ROS1-positive niche, so peak sales are inherently capped and depend on diagnostic testing rates and competition from Roche's Rozlytrek and BMS's Augtyro. Reported profitability in Q1 2026 was flattered by a one-time Eisai upfront, and recurring product revenue is still small relative to a market capitalization around $1.7 billion. The company has issued equity (a 2026 shelf/offering) and could dilute further, and much of the pipeline beyond taletrectinib is early-stage with binary trial and regulatory outcomes. As a single-product commercial company, any launch stumble, pricing pressure, or safety signal would weigh heavily on the shares.
How is Nuvation Bio Inc. (NUVB) valued? (approximate, July 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Nuvation Bio Inc.'s investor relations page or your broker.
- Market cap: ~$1.7B
- Share price (mid-2026): ~$4.80
- Revenue (TTM): ~$130M (boosted by one-time license upfronts)
- IBTROZI product revenue (Q1 2026): ~$18.5M
- Cash and marketable securities: ~$534M
- Q1 2026 net income: ~$5.4M (aided by Eisai upfront)
Reported TTM revenue is inflated by large one-time collaboration upfronts, so the recurring product run-rate (roughly $74 million annualized and growing) is a more conservative gauge of the commercial base. With over $500 million in cash against a market capitalization near $1.7 billion, the balance sheet is well funded, and the valuation largely reflects expectations for future IBTROZI growth and royalty streams rather than current recurring sales.
Who competes with Nuvation Bio Inc. (NUVB)?
ROS1 inhibitor rivals
IBTROZI competes directly with other ROS1-targeted lung cancer drugs, including Bristol Myers Squibb's Augtyro (repotrectinib), Roche's Rozlytrek (entrectinib), and Pfizer's older Xalkori (crizotinib). These are the drugs oncologists weigh against taletrectinib for the same patient population.
Large oncology pharma
Pfizer, Bristol Myers Squibb, and Roche bring far larger commercial, manufacturing, and clinical footprints, which lets them compete on access, sales reach, and next-generation programs across targeted lung cancer.
Emerging targeted-oncology biotechs
Nuvation sits among precision-oncology developers pursuing niche mutation-defined cancers (ROS1, IDH1, and beyond). These smaller companies compete for the same investor capital, clinical sites, and eventual partner deals.
How to invest in Nuvation Bio Inc. (NUVB)
There are three common ways to get NUVB exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so NUVB sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where NUVB fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Nuvation Bio Inc. (NUVB)
Nuvation Bio has crossed from a clinical-stage bet into an early commercial oncology company, and the debate now is how large and fast IBTROZI sales scale against a well-funded field of ROS1 rivals.
More on Nuvation Bio Inc. (NUVB)
Whether NUVB is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is NUVB a buy?, and where the stock could go from here in the NUVB stock forecast.
For income investors, whether NUVB pays a dividend and how the payout looks is covered in does NUVB pay a dividend?
Build a basket around NUVB with Walnut
Use Nuvation Bio Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What does Nuvation Bio (NUVB) do?
+
It is an oncology company that develops and now sells cancer therapies. Its lead product, IBTROZI (taletrectinib), is an FDA-approved oral drug for ROS1-positive non-small cell lung cancer, and it has an earlier-stage pipeline of other cancer candidates.
Is Nuvation Bio profitable?
+
It reported a small net profit in Q1 2026, but that was largely driven by a one-time upfront license payment from Eisai. Underlying recurring product revenue is still modest, so the company is not yet consistently profitable on core operations.
What is IBTROZI (taletrectinib)?
+
IBTROZI is Nuvation's next-generation oral ROS1 tyrosine kinase inhibitor. It won full FDA approval in June 2025 for locally advanced or metastatic ROS1-positive non-small cell lung cancer and is listed as a preferred option in NCCN treatment guidelines.
How much revenue does Nuvation Bio generate?
+
IBTROZI net U.S. product revenue was about $18.5 million in Q1 2026 and growing sequentially. Reported trailing revenue is higher (around $130 million) because of large one-time collaboration upfronts from partners like Eisai.
Who are Nuvation Bio's competitors?
+
In ROS1-positive lung cancer, IBTROZI competes with Bristol Myers Squibb's Augtyro, Roche's Rozlytrek, and Pfizer's Xalkori. More broadly, Nuvation competes with large oncology pharma and other targeted-oncology biotechs for patients and capital.
What are the main risks for NUVB?
+
Key risks include a small ROS1-positive niche that caps peak sales, competition from larger rivals, heavy reliance on a single product, potential equity dilution, and early-stage pipeline programs with uncertain trial and regulatory outcomes.
How is Nuvation expanding IBTROZI outside the U.S.?
+
It has licensed taletrectinib to Eisai for Europe and other markets, to Innovent in China (sold as Dovbleron), and to Nippon Kayaku in Japan. These deals bring upfront payments, milestones, and tiered royalties as approvals expand.
How financially stable is Nuvation Bio?
+
The company held roughly $534 million in cash and marketable securities as of early 2026, against a market capitalization near $1.7 billion. That balance sheet gives it meaningful runway to fund the IBTROZI launch and pipeline, though it may still raise additional capital.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Nuvation Bio Inc.'s investor relations page or your broker before making investment decisions.